Font Size

Drug Utilization Review Board

Drug Utilization Review Board members pictured: (1st row) Tanya Fitts, M.D., Patrick Bynum, M.D., (2nd row) Kristi Phelps, R.Ph., Bobbie West, M.D., Ray Montalvo, M.D., Holly Moore, Pharm.D., (3rd row) Chrysanthia Davis, Pharm.D., Jahanzeb Khan, M.D., Joshua Pierce, Pharm.D., (4th row) Terrence Brown, Pharm.D., Joseph Austin, M.D. (not pictured: Lauren Bloodworth, Pharm.D.)

DUR Board Overview

The Mississippi Division of Medicaid’s Drug Utilization Review (DUR) Board is a quality assurance body which seeks to assure appropriate drug therapy to include optimal beneficiary outcomes and appropriate education for providers and beneficiaries. The Board reviews utilization of drug therapy and evaluates the long-term success of the treatments.

Mississippi Evidence-Based DUR Initiative

Working closely with Mississippi Medicaid staff, the Mississippi Evidence-Based DUR Initiative (MS-DUR) performs retrospective drug utilization review (DUR) functions through claims review and analysis. This important work is vital to the activities of the DUR Board.

In addition to supporting Mississippi Medicaid and the DUR Board, MS-DUR’s work also results in the production of many research reports, clinical presentations, and publications. Please visit the MS-DUR website for access to this important information, as well as helpful resources for Medicaid providers.

Recent articles/submissions:

Factors influencing Human papillomavirus (HPV) vaccination series completion in Mississippi Medicaid. 

Inguva S, Barnard M, Ward LM, Yang Y, Pittman E, Banahan BF 3rd, Kirby TR, Noble SL.  Vaccine. 2020 Feb 18;38(8):2051-2057. doi: 10.1016/j.vaccine.2019.12.030. Epub 2020 Jan 21. PMID: 31980196.


DUR Board Meeting Resources


The DUR Board is composed of twelve participating Medicaid providers who are in good standing with their representative organizations.


Meetings will be held at 1:00 pm in Woolfolk Building Room 145 unless otherwise noted. 2023 dates are as follows:

  • March 2, 2023 (Room 117, Woolfolk Building – no virtual options, live meeting);
  • June 15, 2023 (Room 145,Woolfolk Building);
  • Sept. 7, 2023 (Room 145, Woolfolk Building),
  • Dec. 7, 2023 (Room 145, Woolfolk Building)

Important Updates: Beginning October 1, 2021, pharmaceutical and industry members, vendors, and general public must register to attend. Registration will open thirty (30) days prior to the meeting date. Registration will close at 12pm (noon) the day before the meeting. Due to the ongoing pandemic, only one representative per company may register/attend. Public speaking is not allowed at DUR meetings unless called on by the Board.

Parking: parking may be found on the perimeter of the Woolfolk Building, on the north side of the Woolfolk Building located at the old Wright and Ferguson building (yellow/brown building), and at the Division of Medicaid and First Baptist Church main parking lots at the corner of High Street and North President Street. Guests may not park at the Woolfolk Building or in any parking space marked “Reserved”. 

CLICK HERE to register online for the March 2, 2023 DUR Board meeting! Note: as of 2/14/2023, registration limit (seating capacity for meeting room) has been reached. 
NOTE: Registration is required for all pharmaceutical industry and advocacy representatives to be able to attend DUR Board meetings.

Note: as of 2/14/2023, registration limit (seating capacity for meeting room) has been reached. 

Companies that have met the one (1) representative per company limit (as of 2/23/2023):

  1. Alliant
  2. Gainwell
  3. Gilead
  4. Indivior
  5. Lilly
  6. Magnolia
  7. Molina
  8. Novartis
  9. Novo Nordisk
  10. Provention Bio
  11. Regeneron
  12. Spark Therapeutics
  13. Sunovion
  14. UHC
  15. Vertex
  16. Viking Healthcare Solutions


DUR Board Information DUR Board Packets & Meeting Minutes Archive


Date Agenda Meeting Minutes
March 2, 2023 Agenda Minutes
December 8, 2022 Agenda Minutes
September 15, 2022 Agenda Minutes
June 9, 2022 Agenda Minutes
March 3, 2022 Agenda Minutes